Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385684 | 0.95 | KMT2A (0.41) | KMT2AMEN1CAPN1ALDH1A1ALOX15 | |
| SCHEMBL2386290 | 0.92 | ALDH1A1 (0.43) | KMT2AMEN1CAPN1ALDH1A1ALOX15 | |
| SCHEMBL2385212 | 0.90 | ITGA4 (0.41) | KMT2AMEN1CAPN1ALDH1A1ALOX15 | |
| SCHEMBL2386647 | 0.89 | KMT2A (0.47) | KMT2AFPR2PPARGPPARA | |
| SCHEMBL2385847 | 0.88 | POLB (0.43) | KMT2AMEN1ALDH1A1ALOX15FPR2 | |
| SCHEMBL2385820 | 0.88 | ABCB1 (0.40) | ALDH1A1ABCB1 | |
| SCHEMBL2385988 | 0.86 | MMP8 (0.44) | ALDH1A1ABCB1PPARG | |
| SCHEMBL2386926 | 0.85 | ALDH1A1 (0.45) | CAPN1ALDH1A1ALOX15FPR2 | |
| SCHEMBL2385510 | 0.85 | ALDH1A1 (0.46) | KMT2AMEN1CAPN1ALDH1A1FPR2 | |
| SCHEMBL2384488 | 0.84 | ITGA4 (0.42) | KMT2AMEN1CAPN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017378-B2 | Method for production of optically active biphenylalanine compound or salt or ester thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-1980622-B1 | METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | SUMITOMO CHEMICAL CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1980622-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | DNPEP, APEH, PAH | KMT2A 433/4885MEN1 1396/4885CAPN1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.